ASPIRIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aspirin, and what generic alternatives are available?
Aspirin is a drug marketed by Amneal Pharms, Ani Pharms, Barr, Chartwell Molecular, Dr Reddys, Glenmark Speclt, Micro Labs, Ph Health, Sandoz, Sun Pharm, and Zydus Pharms. and is included in eleven NDAs.
The generic ingredient in ASPIRIN is aspirin; dipyridamole. There are twenty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aspirin
A generic version of ASPIRIN was approved as aspirin; dipyridamole by BARR on August 14th, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ASPIRIN?
- What are the global sales for ASPIRIN?
- What is Average Wholesale Price for ASPIRIN?
Summary for ASPIRIN
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 11 |
| Drug Prices: | Drug price information for ASPIRIN |
| Drug Sales Revenues: | Drug sales revenues for ASPIRIN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ASPIRIN |
| DailyMed Link: | ASPIRIN at DailyMed |
Recent Clinical Trials for ASPIRIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Stanford University | PHASE2 |
| Yale University | PHASE3 |
| Medical University of South Carolina | PHASE3 |
Medical Subject Heading (MeSH) Categories for ASPIRIN
US Patents and Regulatory Information for ASPIRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharms | ASPIRIN AND DIPYRIDAMOLE | aspirin; dipyridamole | CAPSULE, EXTENDED RELEASE;ORAL | 206392-001 | Mar 8, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Micro Labs | ASPIRIN AND DIPYRIDAMOLE | aspirin; dipyridamole | CAPSULE, EXTENDED RELEASE;ORAL | 209929-001 | Aug 11, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Chartwell Molecular | ASPIRIN AND DIPYRIDAMOLE | aspirin; dipyridamole | CAPSULE, EXTENDED RELEASE;ORAL | 204552-001 | Mar 20, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
DrugChatter Q&A for ASPIRIN
How does aspirin's effect on blood vessel dilation help alleviate headaches?
What are the risks of taking aspirin with lipitor?
How does aspirin timing differ for ischemic vs hemorrhagic stroke?
In what ways has aspirin's chemical formula been enhanced in new antiplatelets?
How do other medications affect aspirin's bleeding risk?
What are the risks of taking aspirin with lipitor?
How does aspirin timing differ for ischemic vs hemorrhagic stroke?
In what ways has aspirin's chemical formula been enhanced in new antiplatelets?
How do other medications affect aspirin's bleeding risk?
